Twirla Patch: Effectiveness, BMI Limits, and Side Effects

Twirla is a once-weekly contraceptive patch that delivers two hormones through the skin: a low dose of ethinyl estradiol (a synthetic estrogen) and levonorgestrel (a progestin). The FDA approved it in 2020 specifically for people with a body mass index under 30, making it the first contraceptive patch to carry a formal BMI restriction on its label. That restriction, along with the patch’s lower estrogen dose compared to the older contraceptive patch that dominated the market for years, sets Twirla apart from other hormonal options and raises questions worth understanding before choosing it.

How Twirla Works

The patch is a thin, adhesive square applied to the skin of the abdomen, buttock, or upper arm. It contains 2.3 mg of ethinyl estradiol and 2.6 mg of levonorgestrel, which absorb steadily through the skin over seven days. Like combination birth control pills, these hormones prevent pregnancy primarily by stopping ovulation, thickening cervical mucus, and thinning the uterine lining. The transdermal route skips the digestive system entirely, so the hormones enter the bloodstream at a more consistent rate than a pill swallowed once a day.

You wear one patch per week for three consecutive weeks, then go patch-free for the fourth week, when withdrawal bleeding typically occurs. That completes a 28-day cycle, mirroring the schedule of most monthly pill packs.¹ Remembering to swap a patch once a week is a meaningfully different task from remembering a daily pill, and that difference shows up in real-world compliance data.

Steady Hormone Delivery Over Time

One concern with any weekly patch is whether hormone levels stay stable throughout the wear period and across multiple cycles. Pharmacokinetic modeling of Twirla shows that the answer is yes. After the first week, when levels are still ramping up, the patch reaches a steady state that barely changes even over extended use. Between week 3 and week 12 of continuous cycling, the peak concentration of ethinyl estradiol increased by only about 0.2%, and levonorgestrel’s peak rose by roughly 0.9%.² In practical terms, the hormones delivered in month three look almost identical to those delivered in month one, which is reassuring for long-term users.

A key design goal for Twirla was reducing estrogen exposure relative to the older norelgestromin/ethinyl estradiol patch (sold under a different brand), which had come under scrutiny for delivering more estrogen than expected and raising concerns about blood clot risk. Twirla’s steady-state estrogen exposure is comparable to what you would get from a 30-microgram oral contraceptive pill, a level considered low-dose in the hormonal contraception world.³

Effectiveness and the BMI Question

In the Phase 3 trial, Twirla’s overall Pearl index was 5.8 pregnancies per 100 woman-years of use. That number includes all participants, regardless of weight. When the analysis was limited to people with a BMI under 30, the Pearl index dropped to 4.3. For those with a BMI of 30 or above, it jumped to 8.6.⁴ That gap is large enough that the FDA approved Twirla only for people with a BMI below 30.

Why does weight matter? Transdermal drug delivery is influenced by body composition. More subcutaneous fat can alter the absorption rate and the volume of distribution of the hormones, potentially lowering circulating levels below what is needed to reliably suppress ovulation. This effect is not unique to Twirla; other hormonal methods, including some oral contraceptives and the older contraceptive patch, have shown trends toward reduced effectiveness in higher-weight users. The difference is that Twirla’s clinical data were clear enough, and the regulatory environment cautious enough, that the BMI cutoff became an explicit part of the label rather than a footnote in the prescribing information.⁵

For people in the indicated BMI range, a Pearl index of 4.3 is in the ballpark of typical-use effectiveness for combination pills, which hover around 7 to 9 pregnancies per 100 woman-years when real-world adherence lapses are factored in. Twirla’s number reflects trial conditions, which tend to produce better adherence than everyday life, so real-world effectiveness may be somewhat lower. Still, the patch’s weekly schedule does offer a genuine compliance advantage over daily dosing.

Compliance Compared to the Pill

In a Phase 3 trial that directly compared Twirla to a once-daily oral contraceptive, self-reported noncompliance after six cycles was 10% in the patch group versus about 21% in the pill group. That difference was statistically meaningful and held regardless of whether participants were obese or not. When researchers verified compliance with laboratory testing rather than relying on self-reports, both groups showed noncompliance rates of 10 to 14%, narrowing the gap somewhat but still favoring the patch.⁶

Older data on earlier contraceptive patches told a similar story: compliance was higher across all age groups with a weekly patch compared to a daily oral contraceptive.⁷ The logic is straightforward. Remembering seven things per month is easier than remembering roughly thirty, and a visible patch on your skin serves as its own reminder. For people who have struggled with daily pill routines, this can be a practical reason to consider a patch over oral options.

Does It Stay On?

A patch is only useful if it stays stuck to you. Twirla was specifically engineered with adhesion in mind, and the data on this are encouraging. In a Phase 3 study, investigators rated more than 84% of patches as showing no lift at all at scheduled clinic visits, and participants reported that only about 2 to 4% of patches fell off entirely during wear.⁸ Separate testing under conditions designed to stress the adhesive, including heat, humidity, and exercise, found that adhesion remained excellent throughout.⁹

If a patch does come loose or fall off, the general guidance depends on how long it has been detached. A patch that has been off for less than 24 hours can typically be reapplied or replaced without backup contraception. If it has been more than a day, you would usually need to start a new cycle and use a backup method for the first week. Always check the specific instructions that come with the prescription, since the protocol can vary depending on which week of the cycle the detachment happens.

Skin Irritation

Any adhesive worn on the skin for a week has the potential to cause irritation, and this is probably the most common complaint people have about contraceptive patches in general. For Twirla, investigators rated skin irritation as absent or mild for 97% of patches at clinic visits, and participants themselves rated irritation as absent or mild for 92 to 95% of patches depending on the application site.¹⁰ That means a small percentage of users will notice redness or itching at the patch site, but for most, it is mild enough not to be a real problem. Rotating the placement site each week (switching from the abdomen to the buttock to the upper arm, for instance) helps minimize cumulative irritation in any one spot.

Side Effects and Safety Concerns

The side effect profile of Twirla looks a lot like what you would expect from a low-dose combination hormonal contraceptive. In the Phase 3 trial, the most common hormone-related adverse events were nausea, reported by about 4% of participants, and headache, at roughly 3.6%. About 11% of participants discontinued the study because of side effects.¹¹

The more serious concern involves blood clots. Four participants in the Phase 3 trial experienced thromboembolic events that were judged to be related to treatment, and all four had a BMI of 30 or above.¹² This concentration of clotting events in higher-weight participants was one of the key reasons the FDA restricted the label to people with a BMI under 30.¹³

Blood clot risk is a known feature of all estrogen-containing contraceptives, not just patches. The older contraceptive patch drew particular attention because its sustained estrogen delivery resulted in higher total estrogen exposure than originally anticipated, and epidemiological studies raised questions about whether that translated into higher clot rates.¹⁴ Twirla was designed specifically to address this by pairing a lower estrogen load with levonorgestrel, a progestin that has decades of safety data behind it and is generally associated with a lower clot risk than some newer progestins. For people within the approved BMI range and without additional clotting risk factors (such as smoking, a personal or family history of blood clots, or certain clotting disorders), the thrombotic risk appears comparable to that of low-dose oral contraceptives.

Who Should Not Use Twirla

Beyond the BMI restriction, Twirla carries the same general contraindications as other combined hormonal contraceptives. People who smoke and are over 35 should not use any estrogen-containing method because of a sharply increased risk of cardiovascular events. The same goes for anyone with uncontrolled high blood pressure, a history of blood clots or stroke, certain types of migraine with aura, or estrogen-sensitive cancers. These are not unique to Twirla; they apply across the entire class.

There are also population-specific gaps in the evidence. For example, a recent review of contraceptive options for people with rheumatic diseases noted that no safety data exist for Twirla in people with conditions like lupus (SLE), and the patch is not currently recommended for that population.¹⁵ Lupus already raises the risk of blood clots independently, so adding an estrogen-containing method without specific safety data would be a gamble most clinicians would avoid. Progestin-only methods or non-hormonal options are generally preferred in that setting.

How Twirla Fits Among Other Patch and Non-Daily Options

If you are considering Twirla, you are probably weighing it against other methods that do not require daily attention. The older contraceptive patch (norelgestromin/ethinyl estradiol) is still available and works on the same weekly schedule, but it delivers a higher dose of estrogen, which was the source of the VTE concerns that dimmed its popularity. Twirla offers meaningfully lower steady-state estrogen exposure while maintaining the same weekly convenience.

The vaginal ring is another non-daily combined hormonal option. It sits in the vagina for three weeks and is removed for one week, delivering estrogen and a progestin locally. Its systemic estrogen exposure is lower than the older patch, and it does not carry a BMI restriction, which makes it an option for people excluded from Twirla by weight. Newer ring products can be left in place for a full year, further reducing the number of user actions required.

Long-acting methods like the hormonal IUD, the implant, and the injection occupy a different tier of “set it and forget it” contraception. Their typical-use effectiveness is substantially better than any patch or pill because they remove user compliance from the equation almost entirely. For someone whose primary concern is maximizing pregnancy prevention, these methods remain the most effective reversible options available. But they involve a clinical procedure for placement or removal, and some people prefer methods they can start and stop on their own. Twirla’s appeal lives in that middle ground: more forgiving than a daily pill, more user-controlled than an implant.

What Happens If You Miss a Patch Change

Late patch changes are more forgiving than missed pills, but they are not consequence-free. Twirla is designed to deliver hormones over a seven-day period, and there is some buffer beyond that, but the prescribing information does set limits. If you are late replacing a patch by more than two days (that is, the current patch has been on for more than nine days), the usual recommendation is to apply a new patch immediately, treat that as day one of a new cycle, and use backup contraception for the first week. The patch-free interval is the riskiest time for a late restart, because the ovaries have had a full week without suppression and could resume activity quickly if the hormone-free gap extends further.

This is worth knowing because the most common real-world failure mode for any cyclic method, whether pill, patch, or ring, is extending the hormone-free week. Forgetting to start the new cycle on time gives the ovaries a chance to wake up, and if ovulation happens before you get the next patch on, a pregnancy can result. Putting a recurring weekly reminder on your phone is a low-effort safeguard that can make a real difference.

Disposal and Practical Handling

Used patches still contain residual hormones. After removal, you should fold the patch in half so the adhesive side sticks to itself, then place it in a sealed bag before throwing it in household trash. Flushing is generally discouraged because synthetic hormones can enter waterways. Some pharmacies offer take-back programs, though availability varies. Keeping used patches out of reach of children and pets matters, since even a used patch can deliver a dose of hormones through skin contact.

Storage before use is straightforward: patches should stay in their sealed pouches at room temperature until you are ready to apply one. Do not refrigerate them or store them in direct sunlight. When you open the pouch, apply the patch right away rather than letting it sit. These are small details, but they protect the adhesive quality and hormone integrity that make the patch work as designed.

Insurance Coverage and Access

Under the Affordable Care Act, most private insurance plans in the United States are required to cover FDA-approved contraceptive methods without cost-sharing. In practice, this means Twirla should be available at no out-of-pocket cost on many plans, though insurers sometimes require you to use a generic equivalent when one exists. Since Twirla is still a branded product without a generic version, some plans may require prior authorization or steer you toward the older patch or oral contraceptives first. If your insurer pushes back, your prescriber can usually file an appeal explaining why Twirla is medically appropriate for you specifically. Manufacturer copay assistance programs also exist for people with commercial insurance, and patient assistance programs may be available for those who are uninsured, though the specifics change frequently enough that checking the manufacturer’s website at the time of your prescription is the most reliable move.